BackExelixis Overview

Exelixis Current Cash

Track Exelixis's current cash ($280M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$281.45M
↑ 210.43% YoYΔ $190.78M vs prior year quarter

Peer average

Loading

Exelixis Current Cash History

Loading

Exelixis vs. peers: Current Cash Comparison

Loading

Exelixis Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Exelixis (EXEL) FAQ

Exelixis (EXEL) currently reports a current cash of $280M as of July 2026. That compares with $91M in the prior-year period — up 210.4% year over year. Use the charts on this page to explore Exelixis's current cash history and peer comparisons.

Exelixis's current cash increased from $91M to $280M — a 210.4% year-over-year increase (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Exelixis reported $280M in current cash as of July 2026. That compares with $91M in the prior-year period — up 210.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $280M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Exelixis, and consider following EXEL for alerts when major investors trade the stock.

Exelixis is classified in the Healthcare sector. On current cash, it currently shows $280M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EXEL with unrelated industries.